How to close the age gap in clinical cancer research?
From geriatric assessment to artificial intelligence, an ESMO/SIOG paper highlights effective strategies to improve the representation of older patients in clinical trials
Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
Trustworthy and explainable AI – a key to equitable oncology?
Mitigating research biases by rigorous data analysis and validation can pave the way for a wider adoption of artificial intelligence in cancer care
RAS inhibition: a game changer in pancreatic cancer?
Preclinical findings show antitumour activity of triple KRAS inhibition in mouse models, but it will take years of rigorous research to assess its clinical efficacy in oncology patients
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
Cancer Research
Rethinking the immunotherapy paradigm for a sustainable and equal cancer care
Dose optimisation of immune checkpoint inhibitors may help address current healthcare resource constraints and improve treatment access
Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
Study provides prospective validation of an alternative biopsy technique
Data shows that index lesion-focused ipsilateral systematic biopsy is not inferior to standard systematic biopsy